- The evolving understanding of histology as an endpoint in ulcerative colitis
-
Akiyama S, Miyatani Y, Rubin DT
- KMID: 2560290
- Intest Res.
- 2024 Oct;22(4):389-396.
- doi: 10.5217/ir.2023.00120
A therapeutic goal for patients with ulcerative colitis (UC) is deep remission including clinical remission and mucosal healing. Mucosal healing was previously defined by endoscopic appearance, but recent studies demonstrate... -
- CITED
-
- Close
- SHARE
-
- Close
- De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease
-
Miyatani Y, Kobayashi T
- KMID: 2540407
- Gut Liver.
- 2023 Mar;17(2):181-189.
- doi: 10.5009/gnl220070
Inflammatory bowel disease is a chronic disease of unknown origin that requires long-term treatment. The optical duration of maintenance treatment once remission has been achieved remains unclear. When discussing a... -
- CITED
-
- Close
- SHARE
-
- Close
- Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
-
Karashima R, Sagami S, Yamana Y, Maeda M, Hojo A, Miyatani Y, Nakano M, Matsuda T, Hibi T, Kobayashi T
- KMID: 2560297
- Intest Res.
- 2024 Oct;22(4):473-483.
- doi: 10.5217/ir.2023.00135
Background/Aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
